Every GLP-1 Receptor Agonist Compared

GLP-1 Drug Class

7 drugs in the GLP-1 class

The GLP-1 receptor agonist class now includes seven approved drugs spanning three generations of peptide engineering. Head-to-head trials show tirzepatide produces the greatest weight loss and HbA1c reduction, with semaglutide second.

Frias et al., New England Journal of Medicine, 2021

Frias et al., New England Journal of Medicine, 2021

View as image

Seven GLP-1 receptor agonists are now FDA-approved for type 2 diabetes, with several also approved for obesity. They share a common mechanism, activating the GLP-1 receptor to enhance insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite, but they differ substantially in molecular structure, dosing frequency, efficacy magnitude, and cardiovascular evidence. For a breakdown of how dosing frequency affects performance, see our guide to short-acting vs long-acting GLP-1 agonists.

The drugs: a chronological overview

First generation: exenatide (2005)

Exenatide was the first GLP-1 receptor agonist to reach the market. Originally isolated from the saliva of the Gila monster lizard (Heloderma suspectum), it shares 53% sequence homology with human GLP-1. Exenatide was initially approved as twice-daily Byetta (2005), then reformulated as once-weekly Bydureon (2012) using microsphere extended-release technology.

Exenatide reduces HbA1c by approximately 0.8-1.5% and produces modest weight loss of 2-3 kg. Its cardiovascular outcome trial (EXSCEL) showed a non-significant trend toward cardiovascular benefit but did not meet its primary endpoint for superiority.^[1] In the GLP-1 hierarchy, exenatide is now the least potent option, but it was the drug that proved the concept.

Liraglutide (2010)

Liraglutide was the first human GLP-1 analog (97% sequence homology with native GLP-1). A fatty acid side chain enables albumin binding, extending the half-life to approximately 13 hours and allowing once-daily dosing. It is marketed as Victoza (up to 1.8 mg for diabetes) and Saxenda (3.0 mg for obesity).

Liraglutide reduces HbA1c by 1.0-1.5% at diabetes doses and produces weight loss of approximately 5-8% of body weight at the 3.0 mg obesity dose. The LEADER cardiovascular outcome trial demonstrated a 13% reduction in major adverse cardiovascular events (MACE) in high-risk type 2 diabetes, establishing GLP-1RAs as cardiovascular protective agents.^[2]

Dulaglutide (2014)

Dulaglutide (Trulicity) is an Fc-fusion protein: two GLP-1 analogs linked to a modified IgG4 Fc domain. This structure extends the half-life to approximately 5 days, enabling once-weekly dosing. The device is a pre-filled, single-use auto-injector that does not require patients to handle needles.

Dulaglutide reduces HbA1c by 1.0-1.6% and produces weight loss of 3-5 kg at the 1.5 mg dose. Its cardiovascular outcome trial (REWIND) demonstrated a 12% MACE reduction and was notable for enrolling a broader population with lower baseline cardiovascular risk than other GLP-1RA trials.^[2]

Semaglutide (2017-2019)

Semaglutide represents a significant step up in potency. Structural modifications (an alpha-aminoisobutyric acid substitution at position 2 plus an optimized C-18 fatty diacid side chain) produce a half-life of approximately 7 days. It is available as injectable Ozempic (0.25-2.0 mg weekly for diabetes), injectable Wegovy (2.4 mg weekly for obesity), and oral Rybelsus (3-14 mg daily for diabetes, with a 25 mg dose in development for obesity).

Semaglutide reduces HbA1c by 1.5-1.8% and produces weight loss of 10-15% of body weight at the 2.4 mg dose. In head-to-head trials, semaglutide 1.0 mg was superior to both exenatide ER and dulaglutide 1.5 mg for HbA1c reduction and weight loss.^[3] The SELECT cardiovascular trial showed a 20% MACE reduction in obese patients without diabetes, extending cardiovascular benefit beyond the diabetic population.^[2]

The development of oral semaglutide represented a separate technological achievement. Rybelsus uses SNAC absorption enhancement technology to deliver the peptide through the stomach lining, achieving approximately 1% oral bioavailability.^[4]

Lixisenatide (2016)

Lixisenatide (Adlyxin) is a once-daily, short-acting exendin-4 derivative primarily used in combination with basal insulin (as Soliqua, combined with insulin glargine). Its cardiovascular trial (ELIXA) showed safety but not superiority versus placebo for MACE. Lixisenatide's niche is its pronounced effect on postprandial glucose through gastric emptying delay, making it complementary to basal insulin rather than a standalone agent.

Tirzepatide (2022)

Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) is the first dual GLP-1/GIP receptor agonist. It activates both the GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, a combination that produces greater weight loss and glucose reduction than GLP-1 activation alone. The molecule is engineered with a C-20 fatty diacid side chain for once-weekly dosing.

Tirzepatide reduces HbA1c by 2.0-2.3% and produces weight loss of 15-22% of body weight depending on dose (5, 10, or 15 mg). In the SURPASS-2 head-to-head trial against semaglutide 1 mg, tirzepatide at all three doses was noninferior and superior for HbA1c reduction, with the 15 mg dose achieving a 2.30% reduction versus 1.86% for semaglutide. Weight loss differences favored tirzepatide by 1.9, 3.6, and 5.5 kg at the 5, 10, and 15 mg doses respectively.^[5]

Head-to-head data: what the trials show

Tirzepatide vs. semaglutide

The SURPASS-2 trial (Frias et al., 2021, NEJM) is the most cited head-to-head comparison. All three tirzepatide doses beat semaglutide 1 mg for both HbA1c and weight.^[5] A caveat: the trial compared tirzepatide's full dose range against semaglutide 1 mg, not the higher 2.0 mg or 2.4 mg semaglutide doses used in weight management.

A 2025 NEJM study directly compared tirzepatide and semaglutide specifically for obesity treatment, providing the first head-to-head obesity data at maximum doses. Tirzepatide produced greater weight loss.^[6]

A 2026 systematic review and meta-analysis pooled 12 studies comparing tirzepatide and semaglutide for weight loss. Tirzepatide users lost an additional 4.61% body weight (95% CI: -6.03 to -3.20) and 4.76 kg more (95% CI: -6.09 to -3.42) than semaglutide users.^[7]

For cardiovascular outcomes, a 2026 study in Nature Medicine provided the first comparative cardiovascular data. Both drugs reduced cardiovascular events in type 2 diabetes patients, though the comparative magnitudes are still being clarified.^[8]

Semaglutide vs. dulaglutide vs. exenatide

Among pure GLP-1 agonists, semaglutide consistently outperforms. A 2020 review of once-weekly GLP-1RA head-to-head trials found semaglutide subcutaneous was superior to both dulaglutide and exenatide ER for HbA1c reduction and weight loss. Both semaglutide and dulaglutide demonstrated cardiovascular and renal benefits in their respective outcome trials.^[3]

A 2018 systematic comparison of once-weekly GLP-1RAs confirmed the hierarchy: semaglutide showed the greatest HbA1c and weight reductions, followed by dulaglutide and exenatide ER, with a low risk of hypoglycemia across all three.^[9]

Real-world cardiovascular outcomes

A 2025 study of 21,790 veterans with type 2 diabetes compared liraglutide, semaglutide, and dulaglutide in real-world clinical practice. For kidney failure and cardiovascular outcomes, the three drugs showed no significant differences. Kidney failure hazard ratios were similar across all three agents.^[10]

This finding is clinically relevant because it suggests that while semaglutide produces greater weight loss and HbA1c reduction in controlled trials, the cardiovascular protection may be a class effect shared across GLP-1RAs rather than unique to any single drug.

The emerging hierarchy

Based on the totality of head-to-head evidence, the efficacy hierarchy for weight loss is: tirzepatide > semaglutide > liraglutide (at obesity doses) > dulaglutide > exenatide. For HbA1c reduction, the ranking is similar with tirzepatide at the top.

For cardiovascular outcomes, the evidence is more nuanced. Six cardiovascular outcome trials have been completed for GLP-1RAs, and five of the six human GLP-1-based agents (liraglutide, semaglutide, dulaglutide, and albiglutide) demonstrated MACE reduction.^[2] The exendin-4-based agents (exenatide, lixisenatide) showed cardiovascular safety but not superiority. Whether tirzepatide's dual agonism provides additional cardiovascular benefit beyond GLP-1-only agonists is an active research question.

What the ranking does not capture

Efficacy rankings based on clinical trial means obscure individual variation. Within any trial, some patients on dulaglutide lose more weight than some patients on semaglutide. Response heterogeneity depends on genetics, baseline metabolic state, adherence, diet, and factors not yet characterized.

Tolerability also matters. GI side effects (nausea, vomiting, diarrhea, constipation) are the most common reason for discontinuation across the class. These effects are dose-dependent and typically attenuate over weeks, but they are more pronounced with higher-potency agents. Slow dose titration mitigates but does not eliminate this issue.

Cost and access remain significant factors. In the United States, list prices for GLP-1RAs range from approximately $900 to $1,300 per month, with insurance coverage varying by indication (diabetes vs. obesity) and specific drug. The availability of generic or biosimilar versions varies by market. For an analysis of the economic landscape, see our article on cost-effectiveness of GLP-1s.

Route of administration also differentiates the drugs. Most GLP-1RAs are subcutaneous injections, with dosing ranging from twice daily (exenatide) to once weekly (semaglutide, tirzepatide, dulaglutide). Oral semaglutide (Rybelsus) eliminates the injection but requires strict fasting conditions: it must be taken on an empty stomach with no more than 4 ounces of water, followed by a 30-minute fast before eating or taking other medications. This reduces convenience relative to a once-weekly injection that can be given at any time.

The history of how these drugs evolved from Gila monster venom to the most prescribed drug class in metabolic medicine illustrates how iterative peptide engineering produced progressively more potent molecules across two decades.

What comes next

The GLP-1 class is expanding in two directions: more potent multi-agonists and non-peptide oral alternatives.

Triple agonists. Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously. Phase II data showed weight loss exceeding 24% at 48 weeks, which would represent the largest pharmacological weight loss seen in clinical trials to date if confirmed in Phase III.

Oral non-peptide agonists. Danuglipron (Pfizer) and orforglipron (Eli Lilly) are small molecule GLP-1 receptor agonists that bypass the peptide delivery challenge entirely. Orforglipron has shown promising Phase III results for both diabetes and obesity, achieving weight loss in the range of injectable GLP-1 agonists without the absorption limitations of oral peptides.

Higher-dose oral semaglutide. Oral semaglutide 25 mg and 50 mg tablets are in late-stage development for obesity, with the OASIS program showing weight loss approaching that of injectable semaglutide 2.4 mg.

Combination approaches. CagriSema, combining semaglutide with the amylin analog cagrilintide, represents a different combination strategy that layers two peptide mechanisms rather than building them into one molecule.

The Bottom Line

The GLP-1 receptor agonist class spans seven approved drugs across three generations. Head-to-head trials consistently show tirzepatide (dual GLP-1/GIP agonist) produces the greatest weight loss and HbA1c reduction, followed by semaglutide, then dulaglutide and exenatide. Cardiovascular protection appears to be a class effect for human GLP-1-based agonists. Choice among agents depends on the balance of efficacy, tolerability, route of administration, cost, and individual patient response.

Frequently Asked Questions

Which GLP-1 drug is most effective for weight loss?

Tirzepatide (Mounjaro/Zepbound) produces the most weight loss among approved GLP-1-class drugs. A 2026 meta-analysis of 12 studies found tirzepatide users lost 4.61% more body weight and 4.76 kg more than semaglutide users (Zufry et al., 2026). Tirzepatide's dual GLP-1/GIP receptor activation appears to drive this advantage. Semaglutide (Wegovy) is the most effective pure GLP-1 agonist.

Is tirzepatide better than semaglutide?

For weight loss and HbA1c reduction, tirzepatide outperformed semaglutide in the SURPASS-2 head-to-head trial and in a 2025 NEJM obesity comparison. Tirzepatide 15 mg reduced HbA1c by 2.30% vs 1.86% for semaglutide 1 mg (Frias et al., 2021). For cardiovascular outcomes, both drugs reduce events in type 2 diabetes, but direct long-term cardiovascular comparisons are still emerging.

What is the difference between semaglutide and liraglutide?

Both are human GLP-1 analogs, but semaglutide is more potent. Semaglutide is dosed once weekly (or daily as an oral tablet), while liraglutide requires daily injection. In head-to-head trials, semaglutide produces greater HbA1c reduction and weight loss. Liraglutide was the first GLP-1 RA to demonstrate cardiovascular benefit (LEADER trial, 13% MACE reduction), while semaglutide later showed a 20% MACE reduction (SELECT trial).

Do all GLP-1 agonists reduce cardiovascular risk?

Not equally. Five human GLP-1-based agents (liraglutide, semaglutide, dulaglutide, albiglutide) demonstrated statistically significant MACE reductions in cardiovascular outcome trials. The exendin-4-based agents (exenatide, lixisenatide) showed cardiovascular safety but not superiority versus placebo (Ferrari et al., 2022). Cardiovascular protection appears to be a feature of human GLP-1-based molecules specifically.

Which GLP-1 agonist has the fewest side effects?

GI side effects (nausea, vomiting, diarrhea) are dose-dependent across the class, meaning lower-potency agents like exenatide and lower-dose dulaglutide tend to cause fewer GI symptoms. However, less GI disturbance often correlates with less weight loss. Slow dose titration reduces side effects regardless of the specific agent. No GLP-1 RA is free of GI side effects at therapeutic doses.

Can you take GLP-1 agonists as a pill?

Oral semaglutide (Rybelsus) is the only FDA-approved oral GLP-1 agonist. It uses SNAC absorption enhancement technology to deliver semaglutide through the stomach lining. Oral semaglutide achieves approximately 1% bioavailability, requiring a 14 mg daily tablet to deliver a therapeutic dose. Orforglipron, a non-peptide oral GLP-1 agonist, and oral semaglutide 25 mg for obesity are in late-stage development.